Randomized, Double-Blind, Placebo Controlled, Multi-Center Registration Trial to Evaluate the Efficacy and Safety of TTP488 in Patients with Mild Alzheimer’s Disease Receiving Acetylcholinesterase Inhibitors and/or Memantine

This is a study to evaluate the efficacy and safety of azeliragon in patients with mild Alzheimer's disease. Patients will receive either azeliragon or placebo with a patient's participation lasting approximately 18 months.

Study phase: III

Basic eligibility criteria:
Please contact the study coordinator for additional eligibility information.

1. Males and females (of non-childbearing potential) ages greater than or equal to 50 years of age at screening.
2. Diagnosis of probable Alzheimer's Disease (AD).
3. Participants and caregiver/informants who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.

Protocol number: TTP488-301

Projected enrollment dates: November 2015 to November 2017

Official study title: Randomized, Double-Blind, Placebo Controlled, Multi-Center Registration Trial to Evaluate the Efficacy and Safety of TTP488 in Patients with Mild Alzheimer’s Disease Receiving Acetylcholinesterase Inhibitors and/or Memantine

ClinicalTrials.gov page:
http://www.clinicaltrials.gov/show/NCT02080364

You are here

Randomized, Double-Blind, Placebo Controlled, Multi-Center Registration Trial to Evaluate the Efficacy and Safety of TTP488 in Patients with Mild Alzheimer’s Disease Receiving Acetylcholinesterase Inhibitors and/or Memantine